کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2100272 1082991 2008 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Older adults: Should the paradigm shift from standard therapy?
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی تحقیقات سرطان
پیش نمایش صفحه اول مقاله
Older adults: Should the paradigm shift from standard therapy?
چکیده انگلیسی
For older adults (ie, those age 60 and above) with acute myelogenous leukemia, patient and clinician have three choices: standard therapy, ie, a “3 + 7” regimen or low-dose ara-C, investigational therapy, or palliative care. Investigational treatments sponsored by pharmaceutical companies tend to exclude the 10-20% of older patients who have a poor performance status (Zubrod > 2), an increased bilirubin, or creatinine (> 1.9 mg/ml) and who are thereby unlikely to do well with standard therapy. However, even excluding such patients, standard treatment offers little obvious benefit for most older patients. Nonetheless, these older patients are not uniform and can be stratified to receive investigational therapy, which is mandatory for most, or standard therapy, which is not inappropriate for some.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Best Practice & Research Clinical Haematology - Volume 21, Issue 1, March 2008, Pages 61-66
نویسندگان
,